2 news items
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life
- Prev
- 1
- Next